Group 1 - The report highlights that from January to February 2024, the national fixed asset investment (excluding rural households) reached 50,847 billion yuan, showing a year-on-year growth of 4.2%, which is an acceleration of 1.2 percentage points compared to the entire year of 2023 [59] - In the same period, the total retail sales of consumer goods amounted to 81,307 billion yuan, with a year-on-year increase of 5.5%. Excluding automobiles, the retail sales of consumer goods were 74,194 billion yuan, growing by 5.2% [7] - The industrial added value for large-scale enterprises increased by 7.0% year-on-year in January and February, indicating a stable recovery in production demand [41] Group 2 - The report suggests focusing on investment opportunities in sectors supported by policy initiatives from the Two Sessions, particularly in digital economy, advanced manufacturing, new energy, biomedicine, and low-altitude economy [3] - It also recommends attention to investment opportunities arising from large-scale equipment upgrades and the replacement of consumer goods, particularly in sectors such as engineering machinery, railway equipment, power grid equipment, general industrial equipment, and home appliances [3] - The report notes that the gold industry presents investment opportunities due to an upward trend in gold prices [3] Group 3 - The report indicates that the major stock indices in the domestic market showed mixed performance, with the CSI 1000 index having the highest increase of 0.7%, while the media industry saw the largest gain among sectors with a rise of 9.4% [12][17] - The average daily trading volume in the market was 10,772.2 billion yuan, with a cumulative net inflow of -7.78 billion yuan from northbound funds [46][47]

证券研究报告/行业研究 2024 年快递业开局良好，发展能力稳步增强，关注行业龙头公司 ——快递物流专题研究系列一 投资要点 投资评级: 看好 ➢ 2024年快递业实现良好开局，发展能力稳步增强 分析师：史伟龙 2024年1-2月，快递行业聚焦航空、冷链、跨境等重点领域，我国航空枢纽中心 执业登记编号：A0190523050007 设施建设持续推进，跨境运输网络持续加密，快递企业国际服务能力持续增强。 shiweilong@yd.com.cn 据国家邮政局数据显示，2024年1-2月中国快递发展指数为329.6，同比提升 26.7%。受春节假期影响，假期经济淡旺季特点突出，1月份年货消费活跃，行 业保持较快增长，完成业务量147亿件，日均业务量超4.7亿件。春节假期（2月 10日至17日）完成快递业务量10.8亿件，日均业务量较2023年春节假期增长 145.2%。春节后市场规模快速扩增，行业逐步回归常态化运行，日均业务量约 快递指数与沪深300指数走势对比 4亿件。 50% ➢ 社会物流总额增速稳步回升，物流业总收入保持平稳增长 0% -50% 据中国物流信息中心数据显示，2023年全国社会物流总额352. ...

7d 源达 资料来源：Wind，源达信息证券研究所 重点关注业绩超预期的公司 ——机构调研策略周报(20240318-20240322) ➢ 机构调研热门公司梳理 近一月来外资机构调研次数较多的公司有中控技术、汇川技术和华明装备等。 其中和内资机构调研热度重合度高的公司有中控技术、汇川技术、华锐精密、 东芯股份、汤姆猫、万丰奥威、舍得酒业和周大生。除万丰奥威和因赛集团暂 未披露业绩外，剩余公司中：中控技术2023年业绩表现较佳，汇川技术在宏 观景气度不佳情况下表现出较强的业绩韧性，二者均属于工业控制领域。 建议关注机构调研热度高且业绩表现较佳的公司： 2）石头科技：公司专注于家用智能扫地机器人等清洁电器的研发、生产和销 售。公司持续拓展海内外市场，目前国外营收体量和国内营收基本相当。 5）威胜信息：公司是能源物联网领域领先的解决方案提供商。未来在数字电 网和双碳节能趋势下，国内市场有望保持稳健增长并迎来出海市场机遇。 分析师：褚聪聪 执业登记编号：A0190523050005 chucongcong@yd.com.cn 请阅读最后评级说明和重要声明 一、机构调研热门公司梳理 二、重点公司机构调研公司摘录 | ...

%d 源达 | --- | --- | |----------------------------------------------------------|-------------------------| | | 报告日期:2024年03月15日 | | 本周主要指数全面上涨，关注大规模设备更新和消费品以旧换新 | | | | | | 宏观策略周报 | | ▷ 资讯要闻 2. 3月12日，美国劳工部发布2024年2月份美国CP岗据。2月，美国CPI环比 增速自上月的+0.3%升至+0.4%，同比增速反弹至+3.2%，上月为+3.1%，略 高于市场预期+3.1%；核心CPI环比增速持平于上月的+0.4%，同比增速自上 月的+3.9%降至+3.8%，略高于市场预期+3.7%。 ➤ 市场概览 本周市场日均交易量10334.5亿元，北向资金累计净流入318.2亿元。 ▷ 风险提示 电影 300 指数走势图 | --- | --- | |-----------------------|-------| | | | | 目录 | | | 一、资讯要闻 . | | | 二、市场概览 … | | | 1.主要指数表现 ...

1） 增持：建议关注增持比例较大，公司基本面向好的标的：伊力特、喜临门、 浙江鼎力、林洋能源； -10% -5% 0% 5% 2023/03 2023/08 000300.SH 图表目录 一、A 股上市公司增持情况 | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | |-------|-----------|----------|----------------------|---------------|-------------|----------------------|--------------------------|-----------------------------|--------------------------------------------|--------------------------------------------| | 序 号 | 证券代码 | 证券简称 | 首次公告日期 | 最新公告日 期 | 方 案 进 度 | 股东身份 | 增持 金额 下限 （亿 元） | 增持 金额 ...

证券研究报告/行业研究 国内工控市场有望实现复苏，产品出海拓展成长空间 ——工控设备行业研究系列一 投资要点 投资评级: 看好（首次） ➢ 工控行业受宏观景气度影响大，2024年有望实现复苏 分析师：吴起涤 工业控制系统是设备的大脑，已广泛用于装备制造、印刷、包装、纺织、半导 执业登记编号：A0190523020001 体制造和工业机器人等行业。工控市场可分为项目型市场和OEM市场，二者 wuqidi@yd.com.cn 约各占一半。项目型市场受政府、央企的资本开支影响较大，2023年在电力、 汽车、采矿、化工和公共事业等行业投资需求拉动下项目型市场保持正增长； OEM市场以机床、消费电子、半导体、新能源和机器人等行业为主，2023年 研究助理：程治 上述行业景气度多数不佳导致增速为负。展望2024年，宏观经济进一步好转 执业登记编号：A0190123070008 及消费电子和半导体等行业周期复苏，工控行业有望实现复苏。 chengzhi@yd.com.cn ➢ 控制层国产突破难度最大，驱动层国产品牌已占据较大市场 工业控制器中广泛使用的是PLC，包括中大型PLC（主要用于项目型市场）和 工控设备指数与沪深3 ...

证券研究报告/行业研究 金融信息服务市场有望稳步增长，积极关注有 alpha 效应的公司标的 ——证券分析软件行业研究系列一 投资要点 投资评级: 看好（首次） ➢ 金融信息服务行业市场庞大，未来有望保持稳步增长 分析师：吴起涤 金融信息服务行业即为客户提供证券行情交易、证券分析和金融咨询等服务 执业登记编号：A0190523020001 的行业。金融信息服务行业的细分市场可分为三类：金融数据终端服务、证券 wuqidi@yd.com.cn 行情交易系统服务和网络财经信息服务。金融数据终端服务是第一大细分市 场；证券行情交易系统服务相对来说技术门槛较高；网络财经信息服务对平 台用户的规模要求较高。2023年金融信息软件服务行业中，个人投资者市场 研究助理：程治 和机构投资者市场预计分别达136亿元和49亿元。未来在宏观经济转好及股 执业登记编号：A0190123070008 市监管发力下，A股有望迎来复苏，有望推动金融信息服务行业市场稳步增长。 chengzhi@yd.com.cn ➢ 金融信息服务行业格局相对分散，业内上市公司发展特点各异 国内C端金融信息软件服务行业的上市公司包括东方财富、同花顺、指南针、 ...

Investment Rating - The industry investment rating is optimistic [7]. Core Insights - The GLP-1 class of drugs has become a core target in clinical research for weight loss, with rapid market growth anticipated [2]. - The market for GLP-1 drugs in the U.S. is projected to reach approximately $90 billion by 2030, with the type 2 diabetes drug market accounting for $35-40 billion and the weight loss drug market for $50-55 billion [2][14]. - China has the highest number of diabetes patients globally, with projections indicating that the number of obese individuals will exceed 300 million by 2030 [3]. - GLP-1 drugs not only lower blood sugar but also aid in weight loss and improve various metabolic parameters [4][26]. - Leading global companies in the GLP-1 drug market include Eli Lilly and Novo Nordisk, with Novo Nordisk's semaglutide being the first GLP-1 drug to exceed $10 billion in sales [5][16]. Summary by Sections GLP-1 - GLP-1 was discovered in 1987 and is more effective than GIP in promoting insulin secretion and lowering blood sugar levels [12]. - GLP-1 receptor agonists (GLP-1RAs) have broad pharmacological effects, including increasing satiety and reducing food intake [12]. Potential Market Size - The global diabetes drug market is expected to reach $109.1 billion by 2030, with China's market projected to be RMB 167.5 billion [3][13]. - The obesity population in China is expected to grow from 250 million in 2023 to 329 million by 2030, with a compound annual growth rate (CAGR) of 3.9% [13]. Key Companies 1. **Hengrui Medicine** - Hengrui is a leading Chinese pharmaceutical company with a diverse pipeline in metabolic diseases, including multiple GLP-1 projects [18][20]. - In the first three quarters of 2023, Hengrui achieved revenue of RMB 17.014 billion, a year-on-year increase of 6.7% [18]. - Hengrui's GLP-1 receptor agonist, Noli-tide, is in clinical phase III for obesity treatment [20]. 2. **East China Pharmaceutical** - East China Pharmaceutical has developed a range of GLP-1 products and recently launched liraglutide injection for weight loss [22]. - The company reported revenue of RMB 30.395 billion in the first three quarters of 2023, a year-on-year increase of 9.1% [22]. - The company is advancing multiple GLP-1 projects, including HDM1002 and HDM1005, with various clinical trials underway [25]. Investment Recommendations - The report suggests focusing on companies developing GLP-1 drugs, specifically Hengrui Medicine and East China Pharmaceutical, due to their potential in addressing diabetes and obesity [6][26].

投资要点 ➢ ➢ 40% 30% 20% 10% 0% -10% -20% -30% 000300.SH CI005277.CI ➢ ...

投资要点 ➢ ➢ ➢ 10% 0% -10% -20% -30% -40% -50% 000300.SH CI005011.CI ...